2. Stratified Medicine in the UK
Stratified Medicine in the UK
Vision and Roadmap
Summary Background fewer new drugs. Data shows that, starting
with 5,000-10,000 candidate molecules,
A consortium of government bodies and Even the best medicines are not equally it can take up to 15 years, and cost more
leading charities has joined forces to effective in all patients. Disease processes than $800m, to get one new drug to
accelerate the development and uptake of and treatment choices can vary from market. The sustainability of this model
stratified medicine in the UK. The person to person even though they may of drug development is increasingly
Technology Strategy Board, Medical have similar symptoms. It is estimated that being questioned and many suggest that
Research Council (MRC), Cancer only 30-70% of patients respond positively using molecular biology to select likely
Research UK (CRUK), Arthritis Research to any particular drug. Recent advances in responders could lead to reduced
UK (ARUK), Department of Health (DH), science, particularly in molecular biology development times, fewer failures, and
Scottish Government Health Directorate and genomics, mean that it will become lower costs. Diagnostics companies are
(SGHD) and National Institute for Clinical increasingly possible to identify the an important part of the solution, but
Health and Excellence (NICE) have underlying molecular mechanisms of developing and commercialising robust
formed a partnership to take forward the disease. Developing diagnostic tests that tests can be expensive and difficult.
Stratified Medicine Innovation Platform. indicate the molecular cause of a disease
Together they will invest around £200m enables the development of new treatments
over five years in the area of stratified that can more precisely target the disease,
medicine. Stratified medicine can be as Herceptin does for certain forms of Stratified Medicine
summarised as identifying the right breast cancer. Predicting in advance Innovation Platform
therapy for the right patient at the right time which groups of patients will respond to a
in the right dose. particular therapy and providing treatment Global society faces many challenges.
accordingly is known as stratified By applying technology and innovation we
This publication sets out a shared vision can help to meet these challenges and, at
medicine (or personalised medicine).
for the UK to be the best place to develop, the same time, open up new opportunities
and have adopted, stratified medicine. It Across the world, healthcare models are for business. Innovation platforms focus
also outlines a technology roadmap that facing greater challenges, both physically on specific societal challenges where
describes nine thematic areas which, if and financially, in providing for a growing, government is taking action through
advanced successfully, will help accelerate ageing population with an increasing policy, regulation, procurement or fiscal
the development and uptake of stratified burden of disease. The upward trend in measures. By improving co-ordination
medicine in the UK. The vision and spending means healthcare is becoming between the key players from industry,
roadmap grew out of a series of workshops a more and more significant part of a
academia and government, innovation
attended by more than 100 people nation’s GDP, and the long-term
platforms can identify barriers to meeting
representing a broad range of stakeholders sustainability of current models of
the challenge, map possible routes to
provision is increasingly questioned.
overcoming the barriers, and align activities
A stratified approach has the potential
to support innovative solutions. The aim is
to address some of these issues and at
to deliver a step change in the ability of UK
the same time improve patient outcomes.
businesses to provide solutions for the
Costs are increasing too for the supply global marketplace, boost UK economic
side. Pharmaceutical R&D productivity performance, and provide higher-quality,
is decreasing, meaning higher costs for better value healthcare services.
02 | Technology Strategy Board
3. Vision and Roadmap
The Stratified Medicine Innovation Platform This document presents a summary of the A Shared Vision
(SMIP) seeks to build on the UK’s strength views heard from these sessions in the form
within global healthcare industries and put of a UK Vision for Stratified Medicine in 2025, The vision is for the UK to be the best
it at the centre of the next generation of and a roadmap to achieve it. It attempts to place to develop, and have adopted,
medicine. It is a five-year programme to capture some of the excellent stratification- stratified medicine. This will benefit
accelerate the development and uptake of related activity currently going on in the patients by improving outcomes, help
stratified products and services. The UK, but cannot claim to be comprehensive physicians to select the most appropriate
or an agreed consensus from all of the therapies, increase the cost-effectiveness
innovation platform is a consortium of
represented groups. The current version of of health service provision and help
seven partner organisations all working
the roadmap is a starting point. It will business to innovate more successfully.
towards a common vision. The partners
constantly evolve as new people This vision was developed over a series of
are Technology Strategy Board, Medical
contribute to it, and better understanding workshops which explored what the UK
Research Council (MRC), Cancer Research
is developed. Those interested in engaging landscape should look like in 2025. The
UK (CRUK), Arthritis Research UK (ARUK),
further with the SMIP are encouraged to join key aspects of the vision are given in the
Department of Health (DH), Scottish
the special interest group on _Connect box below:
Government Health Directorate (SGHD)
(https://ktn.innovateuk.org/web/stratified
and National Institute for Health and
-medicines-innovation-platform).
Clinical Excellence (NICE). Each of these
partners in the programme management
group serves a different constituency but
each has agreed to align activities towards A UK Vision for Stratified Medicine
a common goal with benefits for all K The UK should be the best place to develop, and have adopted, stratified
stakeholders. Together they will invest medicine. This will benefit patients, provide cost-effective solutions for the NHS
around £200m in stratified medicine. and other healthcare providers and create opportunities for business
K There should be an increased collaborative culture throughout the sector based
Achieving the rapid development and
around shared resources, and systems should be in place for effective data
uptake of stratified medicine in the UK will
collection, sharing, governance and use across sectors (including NHS,
be a difficult and complex task. It needs all
business, academia, regulators and NICE)
components of the UK infrastructure to
work together around a common plan and K It should be quicker and less expensive to develop new drug-diagnostic
combinations and have them licensed, and success should be reflected in
towards a common goal. The SMIP has
increased UK economic growth
started the process of building a shared
vision for stratified medicine in the UK K It should be possible for all NHS patients to be involved in medical research if
and a plan to achieve it. An early statement they wish, including through use of patient information and records, in order to
of a UK vision was refined and validated inform the next generation of successful therapies
through widespread community K There should be a smooth reimbursement process for stratified therapies and
engagement, including through workshops diagnostics, and an intellectual property (IP) framework that encourages innovation
where more than a hundred people from K The UK health system should have established stratified care pathways, and
more than 70 organisations helped to evidence should be available to show that patient outcomes are improved where
shape and refine the vision and plan. stratified medicine is used
Technology Strategy Board | 03
4. Stratified Medicine in the UK
A Shared Roadmap The UK Stratified Medicine Roadmap
The UK Stratified contains a panel for each of these themes.
A technology roadmap identifies the Each panel describes how things are
long-term objectives in an area and seeks
Medicine Roadmap:
perceived to be now and articulates a
to understand the possible routes to The Nine Themes vision of how they might be in 2025. Some
satisfy them. It can be used to guide the of the barriers to achieving this vision are
1. Incentivising adoption
development of new products, processes presented and activities that would
or services, and to help shape the future 2. Increasing awareness accelerate the development of stratification
direction of an emerging technology. are proposed. Some of the excellent work
3. Patient recruitment –
Developing a roadmap has three major already in train is highlighted. Many topics
consents and ethics
uses. It helps reach a consensus about a are closely interlinked and some occur in
set of needs and identifies a range of 4. Clinical trials more than one panel: for a stratified
possible solutions to satisfy them; it medicine system to work effectively in the
provides a mechanism to help forecast the 5. Data – collection,
UK, many of these issues will have to be
required deployment of those solutions; management and use progressed at the same time. The
and it provides a framework to help plan 6. Regulation and standards Stratified Medicine Innovation Platform on
and coordinate technology and system its own will not be able to achieve
developments. 7. Intellectual property everything that needs to be done, but an
The stratified medicine roadmap describes 8. Bio-banks and biomarkers attempt has been made to show what our
thematic areas which, if advanced own contributions might be. In order to
9. Increasing the impact save space in the following panels,
successfully, will help accelerate the
of R&D investment acronyms are used. These are detailed in
development and uptake of stratified
medicine in the UK. The themes were a glossary at the end of the document.
identified at a series of workshops
attended by a broad stakeholder
community that included commercial
companies developing therapeutics,
diagnostics and data handling solutions;
medical charities; and representatives
from the healthcare sector including
clinicians from across a number of
therapeutic areas, pathologists,
commissioners, managers and
representatives of public sector bodies.
In addition, there were academics
representing research in all of the main
topics around stratification of patients.
The roadmap captures the range of views
expressed by this broad group of
stakeholders. It calls for activity in nine
thematic areas.
04 | Technology Strategy Board
5. 1. Incentivising adoption of SM in the NHS
Barriers
Reimbursement mechanism for SM related Dx tests not Budgets and processes in NHS not designed for A smooth integrated system: fair & beneficial to all
always clear leading to unequal provision diagnostic/drug combinations stakeholders
Current Perceptions
Slow test adoption - commissioning structure a barrier Only few clinical decisions based on genetic tests Equitable access to the right tests for the right patients
at the right time
Future State
Infrastructure is not equally distributed and may be Uncertain markets for point of care testing vs.
sub-scale in some locations centralised testing Infrastructure available to all with equal access to
treatments
Differing requirements for in-house tests compared to Dx companies can struggle to provide data for
industry developed tests independent NICE assessment Tests reimbursed at a level that is cost effective and
incentivises new development
Current NHS genetics policy and services not Uncertain pathology capability in emerging techniques
designed for large-scale testing Patient/public engagement and acceptance
Aggressive national pathology cost savings may
Pathology budgets stretched and not linked to care discourage adoption of new techniques Informed commissioning (quality, cost, turnaround etc)
pathways
No long-term strategic planning in NHS for SM services
Slow adoption of tests without Rx company support
Enablers
Overall framework development by NICE diagnostics arm is an enabler for
Human Genomics Strategy Group value assessment
Enhancing NHS informatics capability National commissioning or funding for
stratified medicine, both tests and
Increasing evidence base leading to
treatments
more widespread clinical acceptance of
the value of genetic tests Value assessment of Dx/Rx combinations
to inform commissioning
Minimally-invasive biomarker tests
Examples of current UK activity Potential Role of SMIP
NHS/DH initiative to improve cancer gene testing Help provide evidence to support policy development for
HGSG review of commissioning, innovation and service delivery in all genetic medicine commissioning and procurement
Ability to use Cancer Drug Fund to buy associated complex diagnostics Help supply chain to develop new business models
Value-based pricing review of drug procurement in NHS Support health economic assessment of diagnostic testing to inform
SMIP/CRUK SMP large-scale demonstrator programme in cancer NHS pricing
Pathology modernisation Support CRUK SMP and other demonstrators by funding associated
Nicholson Review of Innovation in the NHS technology development
OLS Senior Industry Group addressing business-NHS engagement Interim support for innovative molecular diagnostics in adoption phase
NIHR/NOCRI work to improve access for clinical trials Help represent businesses in NHS policy/commissioning development
Trade Associations (ABPI, BIVDA, ABHI, etc.) work with NHS on new commissioning structures
6. 2. Increasing stakeholder awareness
Barriers
Evidence base not conclusive in all therapeutic areas Lack of public awareness of the complexity of Patients understand stratification and accept that
gene-medicine interactions treatment access may depend on a complex test
Some patients may see stratification as a method
Current Perceptions
of rationing Lack of high-quality, clinically approved, education Stratification tests included in education materials
material for patients and practitioners around patient care pathway
Future State
Variable knowledge of how to apply a test in
clinical practice Pace of change of evidence base Appropriate testing for multiple biomarkers
incorporated in clinical care pathway
Emerging models for clinical decision support do The difficulty of integrating clinical imaging and
not always convince clinicians laboratory data
Test usage inconsistent across providers
Enablers
More awareness among front line staff of clinical utility and benefits Development of tests for use at point of prescription (pharmacy/GP) or
patients able to test themselves
Agreement and sharing of genetic medicine health economic analyses
Centralised communication resource to suit a range of health professionals
Tools for physicians to provide clear interpretation of complex test results
Better engagement with patient support groups in disease specific areas
Physician-driven development of education materials for healthcare
professionals involved in genetic medicine Patient access to global communication channels
Examples of current UK activity Potential Role of SMIP
Education working group of the HGSG Develop decision-making tools for physicians
Various bodies already developing guidance materials Develop communication resource for education of health
professionals
Appointment of NHS Chair in Pharmacogenetics
Involve patient support groups and Royal Colleges in SMIP
CRUK large-scale demonstrator in cancer
programme development
Accelerate and communicate programmes that demonstrate validity
of approach
Help extend approach into other therapeutic areas
7. 3. Patient recruitment (consents & ethics)
Barriers
Identifying and recruiting appropriate patient cohorts Data held in a range of databases and formats across A streamlined process for trials consent and patient
can be time-consuming healthcare providers recruitment, and trials are safe
Current Perceptions
R&D approval process can be complex and time- Data quality may be low in data that has not been Consent for broad and unspecified future use,
consuming monitored and audited supported by appropriate regulation of personal data
Future State
When patient consents are study or site-specific, data Inconsistent processes and standards for research Single, and internationally valid, consent and ethics
cannot be used for other purposes consents approval
Sometimes local ethics and R&D approval process can Privacy concerns around data storage and use Primary care has important role in patient recruitment
inhibit larger national studies
Excessive caution from some (unrepresentative) Use of data and samples for research based on
Problems with national programme for IT has held back minority pressure groups ‘opt-out’ rather than ‘opt-in’
novel data solutions
Enablers
Structure of NHS gives unique opportunity to deliver standardised research consent Implementation of Academy of Medical Sciences recommendations on streamlining
research regulation
Novel IT solutions for capturing, communicating, storing and analysing data
Connection of ethics committee with patient groups, starting with current disease
Public engagement about use of samples and genetic data for research
areas of focus like cancer
Development of an overarching ethical framework
Policy communication, IT enablement & governance.
Cost of storing massive data sets decreasing
Education and public awareness campaign demonstrating wider benefits to the
Patient groups support non-restrictive consents and effective R&D approvals community of participation in research
Development and widespread use of generic consent forms Collaboration in clinical trials recognised in clinician performance assessment
Examples of current UK activity Potential Role of SMIP
Academy of Medical Science report and recommendations Engage with patient groups on programme development and
benefits of consent
Leading hospitals already running generic consent for all patient samples
Support Government implementation of AMS recommendations
HGSG working on this area
Consulting with stakeholders on routine/generic consent
Plan for Growth actions on research approvals and recruitment to studies
NIHR Translational Research Partnerships process for research consent in inflammatory disease
Various data access and sharing initiatives (Generation Scotland, Cancer Registries, General
Practice Research Database)
Improved national and international data standards are enabling data sharing
8. 4. Clinical Trials
Barriers
Localisation of commissioning and independence of Uncertain impact of localisation agenda in healthcare Reduced time and cost to conduct clinical trials
providers leads to varied and complex implementation and changes in commissioning
Reduced time to start complex genetic research
Current Perceptions
of national clinical trials
Relative higher prices for trial activities in UK versus projects
NIHR involve patients group BRIC countries
Future State
Reduced cost to recruit the appropriate subjects to
Networks such as NCRI encourage and enable enable stratified medicine
national trials
All patients are able to participate in clinical
Delays before patient recruitment starts is often the trials/population-based genomic research
time-limiting step in studies
Centralised solutions to access rare genetic types
AMS report describes the situation well (e.g. web-based platform)
Exclusion of inappropriate patient populations on
grounds of safety genotypes
Selection of appropriate patients for efficacy testing
Enablers
AMS report and recommendations Develop robust online (internet)
recruitment
National initiatives to improve trials
environment (CRUK, NOCRI, etc) Develop standards within NHS for
provision of patients into clinical trials
Public increasing their levels of
participation in research Better connection of infrastructure
including IT systems and Biobanks
Faster ethics approval based on
patient choice and critical health ‘need’
Examples of current UK activity Potential Role of SMIP
NIHR Clinical Research Networks, including cancer, could help in stratified medicine Similar to role in patient recruitment
NOCRI helping industry engagement with NIHR trials infrastructure Help create critical mass to accelerate trials process
NIHR common frameworks and guidelines to reduce patient recruitment times Communicate unmet needs (prioritisation)
Demonstration of a consistent database of patient accessible
records.
Develop web-based recruitment tools
9. 5. Data
Barriers
Routine data collection and quality variable across the Morale issues following NPfIT failure Population-wide consented patient data available for
UK, better in Scotland analysis by researchers
Most data has not been consented for access
Current Perceptions
NHS Information Centre as central repository and Routine use of anonymised patient data sets by NHS &
Default position is to not make anonymised data
access point for data but currently not meeting industry to improve patient outcomes
Future State
available for research
researcher requirements
Increased use of routine data in post-marketing
Bespoke systems do not or cannot communicate
Government data transparency drive (opengov) surveillance
without significant investment
No national programme for IT Routine collection of health economic data around SM
Data protection issues seen as a barrier within trusts
Range of IT systems in use
Enablers
Massive data sets Implement IT practices and routine generic consent for use
of appropriately anonymised clinical data for research
Public support for research
between institutions
IT capabilities improving
Large-scale demonstrator programmes (regional or
Encourage more open working between academia, therapeutic-area focused)
NHS & industry
Simplification of data protection rules around patient data
Cultural/policy encouragement to share data
Build in and embed quality systems into NHS data handling
Examples of current UK activity Potential Role of SMIP
Generation Scotland Develop tools to allow secure data mining of patient data across
distributed data sources
Individual routine consents
Demonstrate that access to data repository by NHS & industry will
CRUK/Eastern Cancer Registry partnership & SMIP investment in data handling
improve patient outcomes and/or make UK a much better place to
Ongoing improvements to cancer registries do research
Establishment of Patient Reported Outcome Measures (PROMS) by Dept Health in England
10. 6. Regulatory Framework and Development Pathway
Barriers
It can cost over $800m to take a safe and Lack of smart and adaptive study designs Novel design of clinical trials makes smaller cohorts of
effective drug to market, and take 7-9 years from patients possible
Lack of a single body controlling quality of
Current Perceptions
first in-man trials
diagnostic labs Coordinated regulation of pharmaceuticals industry
New drugs sometimes only marginally better than (Rx) and diagnostic industry (Dx)
Future State
Need for regulatory guidance development for
standard care but more expensive
drug-diagnostic combinations Companies make more progress within existing
Different degrees of regulation for pharmaceuticals, regulatory framework
diagnostic tests and laboratories/hospitals
Enablers
Regulatory guidance for co-development Facilitate co-development of drugs and
of diagnostics and treatment diagnostics by alignment of the regulatory
processes
DH and BIS encouraging EU Commission
to improve regulatory framework Setting up of an expert committee
(akin to the Committee for Advanced
Therapies set up by the ATMP Regulation)
Examples of current UK activity Potential Role of SMIP
EU Commission on the revision of the IVD directive Help in novel clinical study design
NHS QIPP agenda includes work on quality and standards Encourage discussion with regulatory agencies
11. 7. Intellectual Property
Barriers
Laboratory-developed tests using unlicensed IP in NHS Questions around effective regulation of laboratory- IP with enhanced licensing for NHS use acts as a driver
discourages development of new diagnostic tests by developed tests of ‘step change’ innovation
Current Perceptions
industry
No single approach to NHS licensing of test technology Publicly funded labs are free to develop safe
Laboratory-developed tests can sometimes save the and effective tests that do not infringe on other
Future State
Patent thickets – multiple IP on sequence reduces
NHS money IP rights-holders
economic attractiveness of panel testing
Some NHS laboratory-developed tests are being Competition between commercial and laboratory-
technically and clinically validated and externally quality developed tests benefits patients
assured
Current IP for gene sequences (BRCA/Myriad etc)
subject to legal challenge
Enablers
Patent box tax incentive Develop IP protection on the test, not the
underlying gene sequence
Excellent technology platform & biomarker
science base Provide a strong home market (NHS) with value
based pricing (product & service) and willingness
Business models for developing & exploiting new
to adopt new tests
& existing IP that provides fair return on
investment whilst maintaining reasonable end A stronger domestic industry with global outlook,
user cost able to capitalise on excellent science base
Examples of current UK activity Potential Role of SMIP
EU In-Vitro Diagnostic consultation in process Provide support for diagnostic companies and co-development
OECD guidelines for licensing genetic inventions Support SMEs in early IP filing
HGC recommendations on IP and DNA diagnostics Commission health economics studies
Support development of new business models and pricing
mechanisms
12. 8. Bio-Banks and Early Biomarker Detection
Barriers
No central overarching database of biomarkers or Localised clinical and research databases are hard to UK-wide database of biobanks is used for
biosignatures use for national level research stratification studies
Current Perceptions
Many biosamples not clinically annotated Lack of technology platforms for use in clinical biomarker All tissue collected with consent for broad clinical
research research and data capture
Future State
Limited standardisation of tissue collection or consent
Require policy framework for biomarker validation Routine, effective collaboration on biomarker ID
Not everyone sees the value of centralised biobanks
Many biomarkers do not have associated therapies A range of early biomarkers identified for future
Stand-alone, incompatible tissue and data
validation
infrastructures
Coordination for Biomarker research via mandated
UK Biobank has recruited 0.5m people
central database
In silico trials to ID biomarker
Enablers
Accreditation system for biobanks Improved biomarker discovery and validation through
new approaches
Improve coordination of funding for biobanks
Linking of databases and biobanks
Standardisation of procedures, including sample
handling storage and consent process Improving IT to enable metadata approach across
multiple systems
Ensuring biobanks store comprehensive clinical data
Increase in pharma collaboration and pre-competitive
Broad & enduring consent or implement opt-out
activity
rather than opt-in for data analysis in research
Examples of current UK activity Potential Role of SMIP
UK Biobank programme standardising access procedures Help develop standards for biobanks
Generation Scotland Map existing UK databases and biobanks
Routine generic consent at sample-acquisition in major teaching hospitals Support development of sample handling & preservation technologies
NIHR/NOCRI Translational Research Partnerships Support development of biosignature analysis and data storage
techniques
Encourage widespread adoption of best practice
Help connect existing infrastructure to create critical mass
Enable access to infrastructure to accelerate development of new tests
and therapies
13. 9. Increasing and Leveraging UK R&D investment
Barriers
Developing new drugs has becoming increasingly Different parts of the system have different objectives Taking drugs from discovery phase to
expensive commercialisation is faster and cheaper, enhancing
Bridging the gap between research and commercial
Current Perceptions
business performance and encouraging investment
Pharmaceutical businesses are re-evaluating their R&D exploitation
investments Stratified medicine offers improved value for money for
Future State
The RAE/REF do not incentivise academics to help
customers including NHS
Turbulence in financial markets has impacted commercialisation
availability of equity and debt finance Improved co-ordination of public and private funding
The sector is extremely large and complex, so major
Public sector funders have not always aligned their change is non-trivial
activities
University funding is changing
NHS needs to save money
Enablers
Creating a coordinated UK programme Better coordinated UK and EU funding
streams
Incentivise stakeholders to share
pre-competitive data Understand the value of cooperative
investment
Stakeholder support for SM
Taking an international perspective
Full audit of UK capabilities /IT,
biomarkers, Dx, Rx, clinical etc
Examples of current UK activity Potential Role of SMIP
ABPI work in this area Commission health economic studies
OSCHR work in this area Help develop new business models for stratified medicine
Nicholson Review of innovation in the NHS Ensure coordination of partner activities
NorthWest exemplar Help create critical mass through a UK-wide programme
Stratified Medicine Innovation Platform investments to date Engage in international programmes
14. Stratified Medicine in the UK
Stratified Medicine The SMIP programme management group
would greatly welcome input from other
Innovation Platform players. The Medicines and Healthcare
Partners products Regulatory Agency (MHRA) and
the National Institute for Health Research
The innovation platform seeks to make the (NIHR)/ NIHR Office for Clinical Research
UK the best place to develop, and have Infrastructure (NOCRI) have already
adopted, stratified medicine products and started working closely with the innovation
services. This is an extremely ambitious platform, and it is hoped that others would
vision that will require activities across also like to participate. There will be areas
multiple technology areas, policy streams where others are better placed to lead,
and government departments. Each of the and we can support their programmes.
Stratified Medicine Innovation Platform
partners has a specific remit and can
contribute significant resources and
expertise from their core areas of
How to engage with us
capability. Together, the group covers a For the UK to achieve the vision set out in
broad spectrum of interests. By aligning this document, significant advancements
activities, many of the issues described in technology and changes to systems
above can be progressed. and processes will be required. This
cannot be achieved by any single
The Technology Strategy Board aims to organisation and will entail coordinated
help businesses to develop innovative new activity across the entire healthcare sector.
products and services, while the Medical This UK Stratified Medicine Vision and
Research Council funds outstanding Roadmap can form the focal point for
research in the science base and has a companies, public sector bodies and
major initiative in stratified medicine. government to coordinate their efforts.
Cancer Research UK is the world’s leading The innovation platform partners have
cancer charity dedicated to saving lives begun this coordinated activity and would
through research, and Arthritis Research welcome help and advice from others
UK has an interest in achieving better whose actions could help accelerate the
outcomes for patients in its disease area: journey towards the ultimate goal.
both have stratified medicine at the centre A web-based community has been
of their strategies. The Department for created to encourage engagement
Health and Scottish Government Health (https://ktn.innovateuk.org/web/stratified
Directorate are government departments -medicines-innovation-platform).
whose main role is to improve health and This will be supported by the innovation
achieve better health, better care, and platform and will highlight future
better value for all. The National Institute workshops, funding calls and ongoing
for Health and Clinical Excellence is discussions on specific stratified-
tasked with assessing medical medicine-related topics. We would also
interventions, both therapies and encourage others to use this forum to share
diagnostics, and recommending their use information, raise awareness, identify
based on value calculations. partners and generate yet more momentum.
014 | Technology Strategy Board
15. Vision and Roadmap
Glossary
ABHI Association of British Healthcare Industries
ABPI Association of British Pharmaceutical Industry
AMS Academy of Medical Sciences
ATMP Advanced Therapy Medicinal Products
BIS UK Department for Business, Innovation & Skills
BIVDA British In-vitro Diagnostic Association
BRIC Brazil, Russia, India and China
CRUK Cancer Research UK
CRUK SMP Cancer Research UK Stratified Medicine Programme
DH Department of Health
Dx diagnostic
HGC Human Genetics Commission
HGSG Human Genome Strategy Group
IP intellectual property
IT information technology
IVD in-vitro diagnostic
NCRI National Cancer Research Institute
NHS National Health Service
NICE National Institute for Health and Clinical Excellence
NIHR National Institute for Health Research
NOCRI NIHR Office for Clinical Research Infrastructure
NPfIT National Programme for IT
OECD Organisation for Economic Co-operation and Development
OLS Office of Life Sciences
OSCHR Office for Strategic Co-ordination of Health Research
PROMs patient reported outcome measures
QIPP quality, innovation, productivity and prevention
R&D research and development
RAE/REF Research Assessment Exercise/Research Excellence Framework
Rx therapeutic
SM stratified medicine
SMIP Stratified Medicine Innovation Platform
Technology Strategy Board | 015
